Q Yu1, Y Niu2, N Liu3, J Z Zhang4, T J Liu3, R J Zhang3, S L Wang3, X M Ding3, X Q Xiao3. 1. Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital; Department of Oncology, Jinghai Hospital, Tianjin. 2. Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. Electronic address: yunniu2000@126.com. 3. Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital. 4. Department of Pathology, Beijing 306 Hospital, Beijing, China.
Abstract
BACKGROUND: Breast cancer is an extraordinarily hormone-dependent tumor. This study was to evaluate androgen receptor (AR) status and its significance in breast cancer in Chinese women. METHODS: Three hundred and thirty-five consecutive cases of invasive ductal breast carcinoma, 34 ductal carcinoma in situ (DCIS), and 82 DCIS adjacent to invasive tissues were involved in this study. The expression of AR was analyzed by immunohistochemistry and compared with patient outcome, and its implications were evaluated in five molecular subgroups of invasive ductal carcinoma (IDC) and in DCIS lesions. RESULTS: AR expression was related to that of estrogen receptor (P < 0.001) and progesterone receptor (P = 0.035) but not correlated with the other conventional parameters. AR retained independent prognostic significance (hazard ratio 0.309, 95% confidence interval, 0.192-0.496; P < 0.001). The majority (61.0%) of basal-like breast cancers showed loss of AR expression (P < 0.001), which had poor prognosis. The percentage of AR-positive cases was significantly higher in DCIS adjacent to IDC group than in pure DCIS and IDC groups (93.9%, 79.4%, and 72.5%; P = 0.046 and P < 0.001, respectively). CONCLUSIONS: Our data suggest that AR may provide another specific definition of breast cancer subtypes and reveal a potential role in DCIS progression. These findings may help develop new therapies.
BACKGROUND:Breast cancer is an extraordinarily hormone-dependent tumor. This study was to evaluate androgen receptor (AR) status and its significance in breast cancer in Chinese women. METHODS: Three hundred and thirty-five consecutive cases of invasive ductal breast carcinoma, 34 ductal carcinoma in situ (DCIS), and 82 DCIS adjacent to invasive tissues were involved in this study. The expression of AR was analyzed by immunohistochemistry and compared with patient outcome, and its implications were evaluated in five molecular subgroups of invasive ductal carcinoma (IDC) and in DCIS lesions. RESULTS:AR expression was related to that of estrogen receptor (P < 0.001) and progesterone receptor (P = 0.035) but not correlated with the other conventional parameters. AR retained independent prognostic significance (hazard ratio 0.309, 95% confidence interval, 0.192-0.496; P < 0.001). The majority (61.0%) of basal-like breast cancers showed loss of AR expression (P < 0.001), which had poor prognosis. The percentage of AR-positive cases was significantly higher in DCIS adjacent to IDC group than in pure DCIS and IDC groups (93.9%, 79.4%, and 72.5%; P = 0.046 and P < 0.001, respectively). CONCLUSIONS: Our data suggest that AR may provide another specific definition of breast cancer subtypes and reveal a potential role in DCIS progression. These findings may help develop new therapies.
Authors: J Feng; L Li; N Zhang; J Liu; L Zhang; H Gao; G Wang; Y Li; Y Zhang; X Li; D Liu; J Lu; B Huang Journal: Oncogene Date: 2016-11-28 Impact factor: 9.867
Authors: Ayca Gucalp; Sara Tolaney; Steven J Isakoff; James N Ingle; Minetta C Liu; Lisa A Carey; Kimberly Blackwell; Hope Rugo; Lisle Nabell; Andres Forero; Vered Stearns; Ashley S Doane; Michael Danso; Mary Ellen Moynahan; Lamia F Momen; Joseph M Gonzalez; Arooj Akhtar; Dilip D Giri; Sujata Patil; Kimberly N Feigin; Clifford A Hudis; Tiffany A Traina Journal: Clin Cancer Res Date: 2013-08-21 Impact factor: 12.531
Authors: Isabell Witzel; Monika Graeser; Thomas Karn; Markus Schmidt; Ralph Wirtz; Dina Schütze; Alma Rausch; Fritz Jänicke; Karin Milde-Langosch; Volkmar Müller Journal: J Cancer Res Clin Oncol Date: 2013-02-08 Impact factor: 4.553
Authors: Ho Sung Park; Jun Sang Bae; Sang Jae Noh; Kyung Min Kim; Ho Lee; Woo Sung Moon; Myoung Ja Chung; Myoung Jae Kang; Dong Geun Lee; Kyu Yun Jang Journal: Transl Oncol Date: 2013-06-01 Impact factor: 4.243